Should Sodium Glucose Co-Transporter 2 Inhibitors Be Considered as First Line Oral Therapy for People With Type 2 Diabetes?
Diabetes, Obesity and Metabolism - United Kingdom
doi 10.1111/dom.13518
Full Text
Open PDFAbstract
Available in full text
Date
October 3, 2018
Authors
Publisher
Wiley